0000875320-24-000142.txt : 20240515 0000875320-24-000142.hdr.sgml : 20240515 20240515161218 ACCESSION NUMBER: 0000875320-24-000142 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240515 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 24950803 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 8-K 1 vrtx-20240515.htm 8-K vrtx-20240515
0000875320VERTEX PHARMACEUTICALS INC / MAfalse00008753202024-05-152024-05-15

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 15, 2024

Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)
Massachusetts
000-19319
04-3039129
(State or other jurisdiction of incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
50 Northern Avenue
Boston, Massachusetts 02210
(Address of principal executive offices) (Zip Code)

(617) 341-6100
(Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.07  Submission of Matters to a Vote of Security Holders
The annual meeting of shareholders of Vertex Pharmaceuticals Incorporated (the "Company") was held on May 15, 2024 (the "Annual Meeting"). Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting:
Proposal No. 1: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider, Nancy Thornberry and Suketu Upadhyay to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2025:
ForAgainstAbstainNon-Votes
Sangeeta Bhatia221,206,626808,512182,98111,540,149
Lloyd Carney213,533,0378,478,558186,52411,540,149
Alan Garber220,695,5871,315,689186,84311,540,149
Reshma Kewalramani221,328,875695,546173,69811,540,149
Michel Lagarde221,776,280234,937186,90211,540,149
Jeffrey Leiden217,823,6434,195,522178,95411,540,149
Diana McKenzie218,220,3653,797,695180,05911,540,149
Bruce Sachs207,616,03314,397,759184,32711,540,149
Jennifer Schneider221,774,054240,910183,15511,540,149
Nancy Thornberry221,772,658241,378184,08311,540,149
Suketu Upadhyay221,237,300770,815190,00411,540,149
Proposal No. 2: Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024:
ForAgainstAbstainNon-Votes
229,460,5233,987,619290,1260
Proposal No. 3: Based upon the following votes, the shareholders approved, on an advisory basis, the 2023 compensation program for the Company's named executive officers:
ForAgainstAbstainNon-Votes
202,098,57519,223,784875,76011,540,149
Proposal No. 4: Based upon the following votes, the shareholders approved a shareholder proposal regarding a special shareholder meeting improvement:
ForAgainstAbstainNon-Votes
160,438,35761,494,550265,21211,540,149
Proposal No. 5: Based upon the following votes, the shareholders did not approve a shareholder proposal regarding a report on racial and gender pay gaps:
ForAgainstAbstainNon-Votes
63,865,687157,637,997694,43511,540,149



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VERTEX PHARMACEUTICALS INCORPORATED
(Registrant)
Date: May 15, 2024
/s/ Jonathan Biller
Jonathan Biller
Executive Vice President, Chief Legal Officer

 EX-101.SCH 2 vrtx-20240515.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 vrtx-20240515_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cover [Abstract] Cover [Abstract] Written Communications Written Communications Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security City Area Code City Area Code Document Period End Date Document Period End Date Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Pre-commencement Tender Offer Pre-commencement Tender Offer Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 vrtx-20240515_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information Document
May 15, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 15, 2024
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA
Entity Central Index Key 0000875320
Amendment Flag false
Entity Incorporation, State or Country Code MA
Entity File Number 000-19319
Entity Tax Identification Number 04-3039129
Entity Address, Address Line One 50 Northern Avenue
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02210
City Area Code 617
Local Phone Number 341-6100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share
Trading Symbol VRTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.vrtx.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - vrtx-20240515.htm 4 vrtx-20240515.htm vrtx-20240515.xsd vrtx-20240515_lab.xml vrtx-20240515_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vrtx-20240515.htm": { "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20240515", "dts": { "inline": { "local": [ "vrtx-20240515.htm" ] }, "schema": { "local": [ "vrtx-20240515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "labelLink": { "local": [ "vrtx-20240515_lab.xml" ] }, "presentationLink": { "local": [ "vrtx-20240515_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://www.vrtx.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240515.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240515.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.vrtx.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0000875320-24-000142-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-24-000142-xbrl.zip M4$L#!!0 ( (>!KUB,EQ+W5Q( +2X 1 =G)T>"TR,#(T,#4Q-2YH M=&WM75MWVLB6?N]?44//=.RU)%#I@B3B9A528301$ETE M;#B_?G:5$ 8#MO"QC2V3EQBI;OO^[;JHCOXQ&8;HFC(>Q-&G#[BL?4 T\F(_ MB*X^?6ATF^WVAW_4?SOZ#U7]^;ES@HYC;SRD48*:C)*$^N@F2 8H&5#T5\Q^ M!=<$780DZ<=LJ*IIM68\FK+@:I @7=/-K%CVEM4TC6 /NYZJ6UY/-1V#J@YQ M?%7K][%K>S[635^YJMF:[_0TEZ@6=GW5I#Y6'=IW5)MB[+B>@ZM57?%KAD9( MU?-MS=)[IN%Y/<^UJ5_M6[ZG>T[?EOT.$J 9Z(YX;1(&T:]/I4&2C&J5RLW- M3?G&*,?LJH)=UZW(MZ5949\&\X*3'@O+G'KEJ_BZ B\J@K:L8#!)EEJ4A46; M003M4<''2L)(Q 6;2 *,%]4U5=-5K&>-3'BP;EBZIN'*S].3KC>@0Z(&$4]( MY-%Y+>@J6-\YU#0J=\L'DTV%L;$PW 7*5*!ZJ4[&A?N(PY:J.:J!LW96F+X\ M2O&Z1W@VRLWB$8*4A6HA 7TMT4C]WBW5CP:4^/6C(4T($E55^OMG^CBST;GM-%L?;]L-QLG M7=0^:Z(*.FT\ON,&.!!?.)$O(;F:]ZB7ZGT2+;<^ O;$?O8+ M[)HEQ^"2ZX(>5;-4H;5WW\V'Z6\HFKW)?F>=5);HSI@TYTIE0>$K8!:I;0CN M! ]YY/\5W+NM,[.G81"I RK"1LW4R[8U2C[>!'XRJ&%-^Z^2+%H_XB,".M%C M0FCIWVD[*ZV),:LD#*ZBF@=,I Q:2$@OI%F!7LQ@[*H7AR$9<5K+_OB8V77J MW519Z>.0L"L87R].DGA8$V.# )H$'@EGGWPRYKZ= 3X%'B9SW/7I?A M567UN>N476W]*ZV,Y?.*;(]E+V=,@T&59!V@1+#F4\DHW2%V-GQ]E" >AX&/ M?M?DOX\CXHOP7],0AE:R+BJ2]IS,%5UF[V$$,:MEC?=!@]0^&0;AM/;A,AB" M&9_1&]2)AR3ZH' ('!!A6-!/"_+@7[2&81CISYN4.!O:D>*8$8MUP=CO9^W+ MUC'J7C8N6]UEA7B%H^VVFM\[[H];/Y9^/L:PLUST]/V]UN^_QL M(PG+ZN="=Z^%J+\('X#F)'&DH.-RLPR0SS+=G(1@YT4H,1^@1#=TH.3+>><4 MY0]I&2Q.D44:T<"O.>JWN^$,O7K-!+WLM,XN4:=U<=ZY?$AX23RJX?R"TPW< MUY]S]!=CQL> 9E 2HR[U! !%V$#G'82M _\0Q7UT"=D*O!JS( F@X];$&P"( MH*CA)>(U=@US:R&M"T,[E:VYECLBM@L:.W04LP0=9+\I@>A.>8+HM4CNF'Q- M@5W;F\"%1 RM%$>44)H& Z8)#4?GJA#:&(@JJD^F:I3Z%FET1P%ENJG9 JB M4F2V^+#QO!+N5Q_23=,$[O\ E$ GZ&) @"<>'4O(P%$;\FT&#)?Y].Z(%65+T)9&;H9=TP M[D5FNVK*S(,7-X'##/SIHPFZX]=#VE_A9\K*TGUA'1J9-:J*%FHP1&OA&4NC M;OKP^2U5?\A24U78,HN^-6&(-]T$++D9CR%[GS9C?]D)BOD3D9 E=,3B:]'. MK?_>%:2NQ .B,4,Q0G \K0_P'JY7Z0XF*(W\&B MXSI\+G/8EM4[M85'L[H9#X1V#=SUC]3RQK>'[C'(^^^\$VL.9*ZV6ZI8&W&#"RB/4@#1NO#*5 MOLNYAV?E2!/^/&>7\8)W%TEP?*%BGM4A_2D9ZS"T!M@5Q!RPGJ MG = '7KL@"Z /A+^3S!*,6;:FPLA5=?QRK+0:\@K\YM^FFG.Z!1A:L2 Y\&( MA(A.J >)\[7(/L$+4'Z(#H '2#!ANS3S54PI5 M;-_5B6UF=TYB"#P7@SBZ ZXQ+M4-$ZM5<->O2.>PMKW281EO;M=#/W"4T)". M!-$HDE0K B^%8Q$_$0$F \?NT[JE\&N5JZN89O9P2_7,\?+E9H72.>,!]7[) M;2!D!"X0S%6@SEX\03T:QCQ8N%":@QM,,0B:;9NWX<0N>BGG#+ M@4!F'!UP2M%7&E$&WJ0=0=UQBH8;9;V<#O>P]KAYQL<#L!>?R[.WB[9_L2 ! M.0F$.XYFV(NOAL!>'(<] DQ/0/1S%Z&7ZG_\[MJF^7%3CI>3]K^ ;8)U_-^B M&FW9ZU-R?,9'8/4B(]%H8=&B,X;4P=2MF3HGRXL58HWB -NH^:6#=$,K0\'- M_J>X^MB-P9T#1Z*K4W TX&W"O,IHO!UE?/Q:6;Z^;YF(AC,NKFHB-@E8\((R M+BV7S571U,IIRHK 95S0,OG[+. MRFZEK+M?477=LF,96R^H6F77U)]D%51/^W^"EG"U7,76*QN442WKAKW](B_8 M[;,M9^FYW*3EE'?A)N5,\@*(3G-&RB#K'*W;+B2#R2R'!)NL/?M2U%/Q]\5G M\^_E^*78,I_N+O(&R L)YUNOAYTV(O#M\?BU[':=R^+ MSV;;G:0FTRQ>@Z^X&03PY-:A;.\J9N%XMH]RPU;LG,P?!KX?TJ+I]Q;3 JF/ MGV*])YW/'+%62W6!?$%@W23V?BGH/[6RAM$%8>@'"<<470 6ZPX(6W/\Y&G- M:2_NIQ/WS/&E?F\N:[M4_]&Y_%EP06*\3I+9TS007L\*!W,D[$CMYQ5:B-)'5>ZJ^IJUU MV^GGC8JD]K;>0K/E)UCD>L9<7XJFM8'-NUE/T!^S(2\CX:NDH)D2D'?:QWVJ M:9^GY,"61P)V8]/]>ZQ4K"FO-?E@98%S 8M/1L8=!3+G'7,J2P%4I\MHXJS MUX',8].SFT*XLJ]P*CJ7Y_6%UD9 &KQA]#K@4 _4JF*5.S$U&STHVTY].TY])A&3B:"$L' MXTYW7, XI#E>QW)LC/)QF'#I#&02.[-6L5DCYF),7$@M2=*=&$34HUFAV=@^ M\&7Z2)+.D"V-977KQ [4-?^FG_3,X(P)8CSZNAST1XX_$(A+^\ MA44(A"ORX9(4LH#0%4Y7?/'B\P \)U'021A/?=0D+*(09!HA4/.5,+F+J4/Y M8$C0-WI#0D9@U(&"3@.(/2$Z(5?@\*F"_DG[?4:GZ(2*+Q$HZ#@@$4&GWC<: M_2N ]Y_9V /@![K$1>$H"OHBAP: +BI )V<03Z;HT93 E4[GKA[)K*K#JD(H]5GQ5ZS[',"3Q^#A@0&P,942 "M,-1_<;(730 MHZD] 08&$[*VT-#EE&OF;5YX,44O.T9UV\44W2@;FOLT2R!VV7;O7VUX\TTY M^;ZQ\'PSJ6F2OG$N]9GV1MY[UN=+S.:&\J@S"Z^0IL85$5] *AY=/4#J050X MNL[B2!60D2]1]DQK;R\<[]-%R>6@G4. &Z<=[YMSW*EHUU.NZUC1M:I2U:OO MB&I' .9Q )ZZ69PKIC=%5>&>RO*):. 'J MV%8<'2)= :&SJ6"!3?0"FIWM**ZUGSAY>^YD>4-&X02H8T<1\R=&M7B)CJ'8 MKBUFA@I'&78T1;,*."=4>'>RL)^K<-+3-; V7%4THWC0!)N* <[$+J+1.4"; M7L 4KO#.9'4_:.&$F,Z=F!#MB@>>==!.%Q=O3@@[AH*M J*NPCN4NYO)"R?" MU)WH2K6 FS-T$RN&73RZ!#[1G )"RL*[DSO'4 HG0;F[UK 50RM>$+=M37%P M 8.XJRF:5CPP>9\WV7A%PQLY+#A?#WAA)_;8PX+BGA=Y/]OL4]UQ$"7RLX5Q M'[58Q!/T!QF./J+_CL?0RLG)A3B7MWP83QR]'5%Y_G;Y0VH]X-_BX?%^P(;R MO*FH+^[Y0U!+O#BFGCSIAPR<'FK=G\@KQC&Z_8F\_8F\+6G:G\A[6W3]6R?R M'OM%K3=V $C77<6L:HJEYTD-BT*UH;B.6&7)LPQ1%)IU@.SX71U@U(J'X8TW MAN'E#3O7U%?$!V)@Q,2_#GC,IJA'>#"K *C:D!]]HA%/K\N!.E>,W +R6T O MOA'FK]RKQ?@>E1<#2N]1^1Z5[U'Y'I6_=U2NZ8KF.HJ5Z^!44:C&KJ+KAF([ M>>:5BT*T8UN*7Q8KJF8EGO"9CJ54O1W]<'[PH,Q:TW!L7](+TH80;)\R!R1DCN_A^!Z.OW,X7C44IRH^Y?>>T#BV M;*5JV(KKOB>JJY" F,:[6@!Y$CB^%L:ES:V]9BQKZ"U>;V6_KNNMI :^R%7 M.:^[ZK:_GC4NOW=:W>>^72[G552S:["&YCV:/FO0;YY;V*=(X_6IW+UD]T\6>C<]IHMKY?MIN-DRYJGS7/ M.Q?GG<9EZWC[N\5WP5K7W15CUP. @UMW<;B9@W<"-D['^R1>[R.KG6FN_:_A%X%%TPRL6W11,%-0D5"=)[NZ,Y] M\?GKRUXJO=B?PG^#9!C6_Q]02P,$% @ AX&O6.^,J59_ @ Q0< !$ M !V9Y)S$>;H$*EM:M4B753 MUVI]FXQ] U83.[,-I/]^L<&#M'0MTA[&"^;><\[]\+WF[+PN"[0";822XXAT MDPB!9(H+.1]']W=7.(W.)YW.V0>,'S[=3M&E8LL2I$47&J@%CM;"+I!= /JA M]*-84?2MH#97NL1XXFD7JGK28KZPJ)?T!@$6O'J4))0PDC'<&[(9'J1]P"E- M.4[RG&2GC)/>@'^ "Z2+@ M^[%SSZB! %]I6[?@SM!EJHQ=JV5,_!WM 23$49O!%PTD'(]4"4E=(6R8.T;1-(EF5Q[:J* MT*9G4\6H]:/P:A,\'KLC)CW<)]W:\"A^5]BVD)#&4LG@F-C-+QQX_R*'W8T> MET/@'9^#%S/ NG.UBCD(?W.'PYO7X.Z W:$=DTJIK.<[R]9654+F:F-H3"[Q M4Y.$SMSTI# MM\DD0%X$:%^!C$GG-U!+ P04 " "'@:]8UC[N MPRT* !]50 %0 '9R='@M,C R-# U,35?;&%B+GAM;,V<76_;.!:&[_LK MN)F;76!8BQ0E446;03?3+HK-M$&;8@8[6!C\3(2QI4!6FN3?+RG;J11+MDC% MZMZTCLV<][RT'_,<2LSK7^Z7"_!-E:NLR-^;EX6917,QP$X6P[^F0S_'YG_%U8CT9IFL[J5Q^' MKK*N@28LFOWQV_D7<:V6#&;YJF*YL *K[-6J?O*\$*RJ9_U@7J!WA/T);H=! M^Q1$&(;HY?U*GIR^ & ]'66Q4)^5!O;_KY\_]$JF,SMBEJLK^]Y>J#(KY)>* ME=4YXVIALJ^C50\WZLW)*EO>+-3VN>M2Z>ZPB[)L1;59IC9+%-LL?^H3FXU( M_YGRK79S?8;D:KL?GRO'?7/Z\=G2O33?$.KX"3=D1J>\_D"]R^54G]U'J=&I M'S_CY_I8%!5;3/"Q^"[32'EAGS@WCS8R-M">+]-:9_/5W4A5W5LI-RF=F+=+JM)4O1WV.CZU9Z;L M+=GB@_FVN/^W>C"XZSA)-8&$R,14I!&":6R8)TDB*56,>AA+E MY\X+IB'&/##:=3""H$:PB>'9M;'+3<<87V3>2FG>L56]XGTJ+\KB6V82G0>Q M%)$6$8QI8E8I+01,<1C ,#2K%HXU8;%PPZ=;:!J4-MJ-4FNK[TI6SW0-I6S\ M)'@1Y^'? \#]YD; V!-X8C#WV]N%],!X=V"_*'%;FL#O[L6U>9/51[94\X3B MB$G3^892(4BB@$-#*(&<*,I-[RB28/ ZUR5P9$"WDF"K":SH<"H[Y^0PC6.= MNE'H:-()O7U.O)#K##@9:OOL-!';.\X=K8O2M'O+I3+YV2L4'U:K6U5>VLV= M\I/6IHR2H:"!%@KBM%X/8P9I( F40K,PY9Q1LPH,Q.R0V)&1,_)0-/3!.@&P MS@#4*0P'\.#,'8;Q.>?####X9OD-M-E$>_#LC2]S-?^=9 MKM"<:+-H1G$$$>8I) E-( ]"#H4D*45A0K!(O>K;ILK$Q>WF ;#:X%/N6]NV MYLFQL/5U/ZZJ'6SQWEJV<_!(+,_,PT_E97&7SR/, MJ:8R@$P$ 22FA+5EK(2"1"$/$*.<.%X$V=&8&$DK;-LM*^V)8V-^'&'TPD;,'X/@KJE> #N&>O21Q2(3697E5[^9UK3,V&(>4X5#3C%4 M&H>0A)A#&G$"A4("ISR0-!I,WF[X8_>0CX)@J^C00.Y.QH#V<91%Q^;1P9U; MY]AKPJ]OW TW7=?8:Z75,_:/&KF&712KBBW^D]W4%Z%#*M-(HPBRT-Z5%BL$ M>8()C&(2I)QAG5+JM8RU9"9>R=;:P(A[7;;OG"C']L;9W6>I>W[M'N<)X5WU3YEJ^JDHEJ'F(MHA29U2P5IM>+4P491QQ& M"NF$:RT8PD-Y;$4^,H*U%OASJ_;?XR,P^'>1KCS@TE!V-.&/4Y\")H)]AD\/39:'+3.\;_LC;"_#*K M%FHNJ$(D52&D2"B##.60\TA!''(449TR0@;?'/DT^)&1J35 H0'"?^?_ %MU M]^O9CY,Q8#-BA$4W;ES=>5W(?FICU$7LQV"37\!^:J/KXO7.&(].QS9/I6)U M/XV%Y$RD'%)I=_%TK.Q-6Q%,DABQ&'-3SPW>Q6L&/G:?4[?;1LMQ9Z'E?4"3 MX^G(L<<99L:MP^G(W*_!:0::KK_I2+_5WG2][H["]GCIXXFJ7UFEYEQ+)64< M0\VE64R$%I %AHF8,QQBEK (QT.9Z%0X,AR/AV;7HL"H BL[')/N>3G,RVBW M;N X&W5":*\9+Y:Z(TX&U5Y#3;KV#_3=^+YD]Q^DB9KI3=.TO>U>ZAB)T!1K M@L:0Q"*%G%()(_.LEI'&"1F\F;!7:9KM;R,.VNJ>=^3WS=?0+?!GF 6O77#W M"?#8!C]@;L1.>%_DB3?##QC9P*)G2<0!D2 M!(F*,:213$S'%:=1)+@BP[?$6Y&/C.6C%K!BPR%LNS\,G;Y(7);,_JV2+P]+7BSF.K2M$Y*0JE!"$C -F;(GRE,B MS2L1P6PP$JW(Q]YR6&N!M=AP)-KN#R/A[@>X%OYBG9 @U<3Q?H:V MP#2EW'=-QR,FG7,RM&[S=^I5K@TUZ5&D=3L949L]"3AQ2=9M9[<2ZQDW^HA) M\X@$9Z;FD@C!&-L-;RZX:9K"$$H5LX32 "LJ/0^7_,!C)<]RGF3429(?*U^]=,?-2F7QUH\KV^9OI= M6WRMUWV+OW=+55Z96O)?97%771O<;EC^,&!:*K=8]"<:^Q$?5B=]R) MR\:]YG:KQ_W#^Q!MOAOGYM'IB^TSV?JO=9Z^^!]02P,$% @ AX&O6,TK M<0.Y!@ ,S$ !4 !V_W;U@>CY#R<' M!^_^1<@?/WZZF/U4^YL-5,WL+(%M(,SNBF8]:]8P^[U.?Q:W=G99VB;6:4/( M27?;67U]GXK5NIEQRK.]V/YJ.J+4,L^,)UQZ1S(M@&BK Z$Q,J-\8#P+WZ^. M% W:46.)9":0# (C&J(F"AC3QFN6Y[R;M"RJ/X_:#V>W,$/WJFWW]WB^;IKK MH\7B[N[N<.=2>5BGU8)3*A9[Z?FC^.Z9_)WHI)DQ9M%=_9_HMGA)$*=EBS]^ MN?CLU["QI*BVC:U\JV!;'&V[P8O:VZ9#_6_MFGU3HOU']F*D'2*,$\$.=]LP M/SF8S1[@2'4)GR#.VN_?/IT_47F;FMVAKS>+]N)B'U];A?=54S3WYU4;S,[2 M_37THINUN;^&X_FVV%R7L!];)XC'\W9.TH:;2B9;6[[K->_B+XNO$VQ;\?;Z M!0X\3M_:.*KUL&N@"O UEYY6?LG0F4;JCKM[RRM@[(;708HEF M ;F'L*"Y\QEZ'2$E"!7,BFSH4A6+XQ M&4XQJ84VL7TH[6HI9' F1$X\56T^TQFQ&B1AFD5J@A;&J4$D>**N5_#E=(/_ M>NPFD0'.L?!+UW7J$/^,P,-9?8-$OC^K RYMU#/*F2!12D:RX($8])!$;606 MF,XA,R/D@_]K1"^"Y-,ER-@X3X(V'XH2?KW9.$A+[:(0U@E"K1=MGN/$2I$1 M*0P56-_G(1MC^_"7QEZ$4%,GQ"L1G$3TK^SN/"!612P>^AF/CG#(M,UT("$J M=$0AETW@G(#.<\D,$X;S$:CP#?6]>*&GSHLQL)T$24Y#P!!L'[\NB@K8,K?" MZX@K(\^](AEWR'3-%6%* /7"4N7S$0CR@NI>Y#!3)\=03*=$C#/\^3%=U7?5 MTKH8C%/V'L.*5@$Z)$]W&Z&.Z M3/5M47E8.F\SPY#6ROJVS^;:\HE'_$5C5,"4S]V3+AE.1JT4Z+( M9;UM;/F?XKK;..Z400=#P+=K(?.&Z&"QCI).Q#P/2OAAK8LOM?4CP(1[ MF*^&[HU#WKY%+2_7=;4OH*(WRCD5B= 9EL]YM,3Q+"/1*JRL59!YI(/"_K7& M?J&?<,MR$(1O'/[?4]$T4)W5F\U-]5@D;9>Y0!P\;G1R9@.FK+;=FBET!2Q6 M2#12*>,@#KRHMA\1)MR^' [F&[/A#"7M^>5=/#WG+\G07]B#+AUN6H$+_U@@+^ M!A?%>\;=5=&4L&0"VHHXX-:(HNU&94337!$:G;5Y8%@J#WO!\;7&?G28<+-R M$(1O'/ZK9-N#L)_O-ZXNEQ&=QHVQ(L$)B6S-/#%,:+1>*@=9D!D-@V+_1%V_ M\U$3[D>^'KR)//3O=WYMJQ5TQWF\$^ HLC;7H'&-,Y)8:C"'Z/B=FVK^Z5B4H1,R?<;AP,[&C_>+9Y!>8$#)P>/%]J/]HS]R<%_ M 5!+ 0(4 Q0 ( (>!KUB,EQ+W5Q( +2X 1 " 0 M !V!KUCOC*E6?P( ,4' M 1 " 882 !V!KUC6/N[#+0H 'U5 5 " 305 !V"TR,#(T,#4Q-5]P&UL4$L%!@ $ - 0 ! $ ( F $! end XML 17 vrtx-20240515_htm.xml IDEA: XBRL DOCUMENT 0000875320 2024-05-15 2024-05-15 0000875320 VERTEX PHARMACEUTICALS INC / MA false 8-K 2024-05-15 MA 000-19319 04-3039129 50 Northern Avenue Boston MA 02210 617 341-6100 false false false false Common Stock, $0.01 Par Value Per Share VRTX NASDAQ false